Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Haploidentical hematopoietic stem cell transplantation using low-dose alemtuzumab is effective for standard-risk hematological malignancies

View Full Paper
Ask AI
Bookmark
Share

Authors

YNYuhei NakamuraMKMachiko KusudaÞHÞorvarður R. Hálfdánarson

Discussion

Loading...

Member takes

Overview

Analysis shows improved outcomes for standard-risk hematological malignancies, highlighting the role of graft-versus-host disease prophylaxis.

Key Points

  • Overall survival rates increased to 80.4% for standard-risk patients since 2021, indicating improved outcomes.
  • Relapse rate reduced significantly in patients with standard-risk disease compared to high-risk counterparts.
  • Haploidentical hematopoietic stem cell transplantation utilized low-dose alemtuzumab and various myeloablative regimens.
  • Results suggest the efficacy of graft-versus-host disease prophylaxis on overall survival in hematological malignancies.

Cite This Study

Nakamura et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db9bhttps://doi.org/10.1182/blood-2025-5995
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Allogeneic hematopoietic stem cell transplantation for hematological malignancies using nonmyeloablative fludarabine, cyclophosphamide, 200 centigray total body irradiation, and post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil for graft-versus-host disease prophylaxis is associated with low non-relapse mortality.2025
  2. 2T cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT2025
  3. 3Results of allogeneic hematopoietic stem cell transplantation from a genoidentical sibling after high-dose treosulfan-based conditioning in children with intermediate-risk acute myeloid leukemia in first clinical and hematological remission2025
  4. 4Impact of allogeneic transplant vs hypomethylating agents in high-risk myelodysplastic syndromes: A prisma-guided systematic review2025
  5. 5Young (35 years) matched sibling donors for allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT2025